Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 11/20 | 0.77 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.77 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.77 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.75 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.75 |
| ▸ | DHODH | Q02127 | 6/20 | 0.60 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.58 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL7318987 | 0.96 | PARP1 (0.72) | PARP1PLA2G2AALOX15PTGS2PKN1 | |
| SCHEMBL29087633 | 0.88 | PKN1 (0.77) | PARP1PLA2G2AALOX15PTGS2PKN1 | |
| SCHEMBL7325071 | 0.88 | PARP1 (0.79) | PARP1PLA2G2AALOX15PTGS2DHODH | |
| SCHEMBL2815222 | 0.88 | PKN1 (0.77) | PARP1PLA2G2AALOX15PTGS2PKN1 | |
| SCHEMBL505325 | 0.88 | PKN1 (0.77) | PARP1PLA2G2AALOX15PTGS2PKN1 | |
| SCHEMBL7322715 | 0.88 | PKN1 (0.81) | PARP1PLA2G2AALOX15PTGS2PKN1 | |
| SCHEMBL18255504 | 0.88 | PKN1 (0.69) | PARP1PLA2G2AALOX15PTGS2PKN1 | |
| SCHEMBL7312040 | 0.88 | PARP1 (0.74) | PARP1PLA2G2AALOX15PTGS2PKN1 | |
| SCHEMBL7319077 | 0.87 | PARP1 (1.00) | PARP1PLA2G2AALOX15PTGS2PKN1 | |
| SCHEMBL22453146 | 0.87 | PKN1 (0.75) | PARP1PLA2G2AALOX15PTGS2PKN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249179-A1 | Farnesoid X Receptor Agonists | SMITHKLINE BEECHAM CORPORATION (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249179-A1 | Farnesoid X Receptor Agonists | SMITHKLINE BEECHAM CORPORATION (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249179-A1 | Farnesoid X Receptor Agonists | SMITHKLINE BEECHAM CORPORATION (US) | 2010-09-30 | — | — | US | disclosed |
| EP-2170072-A1 | FARNESOID X RECEPTOR AGONISTS | GlaxoSmithKline LLC (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008157270-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249179-A1 | Farnesoid X Receptor Agonists | NR1H4, NR1H3, NR1H2 | PARP1 3922/4885PLA2G2A 524/4885ALOX15 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.